Summary
Full summaryExecutive Assessment
Regeneron's 2025 revenue reached $14.3B (+1.0% YoY), with net income of $4.5B (+2.1% YoY) and diluted EPS of $41.48 (+8.2% YoY), driven by strong collaboration revenue growth offsetting a decline in U.S. EYLEA net product sales.
- Total revenues increased 1.0% to $14.3B, as Sanofi collaboration revenue surged 29.8% to $5.9B, primarily from higher Dupixent profits.
- U.S. net product sales of EYLEA declined 42.3% to $2.7B due to biosimilar competition and patient transition to EYLEA HD, while EYLEA HD grew 36.3% to $1.6B.
- Operating income decreased 10.3% to $3.6B, with operating margin contracting to 24.9% from 28.1%, reflecting higher R&D investment and lower gross margin on product sales.
- The company returned $3.8B to shareholders through share repurchases ($3.5B) and dividends ($0.4B), and ended the year with $18.9B in cash and marketable securities.
Financial Highlights
| Metric | Current Period | Prior Period | Change | Investor Takeaway |
|---|---|---|---|---|
Total Revenues | $14.3B | $14.2B | +1.0% | Growth driven by collaboration revenue, partially offset by lower net product sales. |
Net Income | $4.5B | $4.4B | +2.1% | Increase supported by higher other income and lower tax rate, despite lower operating income. |
Diluted EPS | $41.5 | $38.3 | +8.2% | EPS growth outpaced net income due to share repurchases reducing weighted average diluted shares. |
Operating Cash Flow | $5.0B | $4.4B | +12.6% | Improved working capital management and higher net income contributed to cash flow growth. |
Free Cash Flow | $4.1B | $3.7B | +11.3% | FCF increased despite higher capex of $898.4M; FCF conversion from net income was 90.6%. |
Profitability
- Gross margin on net product sales declined to 82% from 86% in 2024, impacted by manufacturing investments, higher inventory write-offs, and increased Libtayo intangible amortization.
- Operating margin fell to 24.9% from 28.1%, as R&D expenses grew 14.0% to $5.9B, including a $155M priority review voucher charge.
- Effective tax rate rose to 13.9% from 7.7%, primarily due to lower stock-based compensation tax benefits and the impact of the OBBBA tax law change.
Cash flow
- Operating cash flow of $5.0B funded $898.4M in capex, $3.5B in share repurchases, and $370.3M in dividends.
- Investing cash outflows narrowed to $629.1M from $2.5B, as net purchases of marketable securities decreased significantly.
- Financing cash outflows increased to $3.7B from $2.2B, driven by higher share repurchases and lower proceeds from stock option exercises.
Balance sheet
- Cash and marketable securities totaled $18.9B, up from $17.9B, providing ample liquidity.
- Total debt of $2.0B and finance lease liabilities of $720M remained stable; no borrowings under the $750M revolving credit facility.
- Working capital decreased to $13.7B from $14.7B, with current ratio declining to 4.13x from 4.73x, partly due to increased current liabilities.
Investment Risks & Concerns
Risk Factor
Substantial dependence on EYLEA HD, EYLEA, and Dupixent; EYLEA faces significant biosimilar competition.
Risk Factor
Product reimbursement and pricing pressures from U.S. and international government actions, including the Inflation Reduction Act and executive orders on drug pricing.
Risk Factor
Intense competition for all major products, including from biosimilars, other anti-VEGF therapies, and PD-1 inhibitors.
Risk Factor
Manufacturing and supply chain risks, including reliance on limited internal and contracted capacity and ongoing expansion projects.
Risk Factor
Potential intellectual property challenges and loss of market exclusivity for key products.
Management Strategy & Execution
Themes
- EYLEA franchise transition: EYLEA HD growth partially offsets EYLEA decline, but competitive pressures and patient affordability constraints persist.
- Dupixent collaboration profit growth remains a key earnings driver, with Regeneron's share of profits reaching 29% of global net product sales.
- Significant R&D investment continues, with direct expenses rising across multiple late-stage programs and a $155M priority review voucher utilized.
- Capital allocation prioritizes share repurchases ($3.5B) and dividends, while capex is expected to increase to $1.1B-$1.3B in 2026 for facility expansion.
Capital allocation
- Share repurchases totaled $3,456.2M in 2025, with $1,486M remaining under authorized programs as of year-end.
- Quarterly dividends of $0.88 per share were paid; a $0.94 per share dividend was declared in January 2026.
- Capex of $898.4M focused on manufacturing and R&D facility expansion; 2026 capex guidance of $1.1B-$1.3B.
- No M&A transactions of material size disclosed; $80M upfront payment for Hansoh Pharma license agreement.
“EYLEA net product sales have been, and are likely to continue to be, negatively impacted by increased competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.”
— Management
“We expect to incur capital expenditures of $1.100 billion to $1.300 billion in 2026, including in connection with the continued expansion of our facilities in Tarrytown, New York and developing our property in Saratoga Springs, New York.”
— Management
Business Segment Analysis
| Segment | Revenue | Change | Commentary |
|---|---|---|---|
| EYLEA HD and EYLEA - U.S. | $4,384.7M | -26.5% | EYLEA HD grew 36.3% to $1,636.9M, but EYLEA declined 42.3% to $2,747.8M due to biosimilar competition and patient transition. |
| Libtayo - Global | $1,452.2M | +19.3% | Growth driven by both U.S. (+20.0%) and rest-of-world (+18.2%) sales. |
| Sanofi Collaboration | $5,884.0M | +29.8% | Regeneron's share of profits from Dupixent/Kevzara increased to $5,241.6M, reflecting higher Dupixent sales. |
| Bayer Collaboration | $1,422.4M | -5.1% | Lower profits from EYLEA sales outside the U.S., with Regeneron's share of profits declining to 37% of ex-U.S. net sales. |
Liquidity & Capital Structure
Leverage: Total debt of $1,985.9M and finance lease liabilities of $720.0M; debt-to-equity ratio of 6.4% (based on long-term debt only). No borrowings under $750M revolving credit facility.
Liquidity: Cash and marketable securities of $18.9B; working capital of $13.7B; operating cash flow of $5.0B. Management believes existing resources are sufficient for foreseeable future.
Shareholder returns
- Repurchased $3,456.2M of common stock in 2025; $1,486M remaining authorization.
- Paid quarterly dividends of $0.88/share; increased to $0.94/share in January 2026.
- Proceeds from stock option exercises declined to $635.9M from $1,465.3M in 2024.
Forward Outlook & Investment Implications
cautiousNo specific revenue or earnings guidance provided. Capex expected to be $1.1B-$1.3B in 2026 for facility expansion. R&D and commercialization costs expected to remain substantial.
Drivers
- EYLEA franchise performance will depend on EYLEA HD uptake and biosimilar competition impact.
- Dupixent profit growth trajectory and potential new indication approvals.
- Pipeline progress, including regulatory submissions and clinical trial outcomes.
Watch items
- Biosimilar EYLEA launches in U.S. expected in second half of 2026.
- Medicare Drug Price Negotiation Program and other pricing reforms.
- Manufacturing expansion execution and associated cost overruns.
Notable Footnotes
| Item | Impact |
|---|---|
| Priority Review Voucher (PRV) utilization | In Q4 2025, the company decided to utilize a PRV purchased in Q2 2025 for $155.0M, resulting in a charge to R&D expense. |
| OBBBA tax law change | Enactment of the One Big Beautiful Bill Act in July 2025 resulted in a $44.5M charge for re-measurement of deferred tax assets. |
| Libtayo intangible asset amortization | Higher amortization expense due to quarterly additions to the intangible asset related to royalties due to Sanofi, contributing to lower gross margin. |
3-Year Investment Perspective
Revenue grew at a 3-year CAGR of 4.5%, but product mix shifted significantly: net product sales declined from $7.1B in 2023 to $6.3B in 2025, while collaboration revenue increased from $5.5B to $7.3B. Operating income declined from $4.0B in 2023 to $3.6B in 2025, while net income grew from $4.0B to $4.5B due to higher other income and lower tax rates.
Inflections
- EYLEA U.S. net product sales peaked at $5.7B in 2023 and fell to $2.7B in 2025, while EYLEA HD ramped from $165.8M to $1.6B.
- Sanofi collaboration revenue grew from $3.8B in 2023 to $5.9B in 2025, driven by Dupixent volume growth and higher profit share percentage.
- R&D expenses increased from $4.4B in 2023 to $5.9B in 2025, reflecting pipeline advancement and PRV charge.
Prior-period comparison
- 2024 revenue of $14.2B was up 8.3% from 2023, driven by EYLEA HD launch and Dupixent growth, while 2025 growth slowed to 1.0% as EYLEA erosion accelerated.
- Operating margin compressed from 30.8% in 2023 to 28.1% in 2024 and 24.9% in 2025, reflecting rising R&D intensity and gross margin pressure.
- Free cash flow improved from $3.7B in 2024 to $4.1B in 2025, but remained below 2023's $3.9B (calculated as $4,594.0M - $718.6M) due to higher capex.
Ask REGN’s 10-K anything
Get plain-English answers, each cited to the exact filing text. Try a starter question:
AI-generated. Informational only, not investment advice. May be incomplete or contain errors. The authoritative source is always the original SEC filing.